Clinical trial
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
NCT00485758 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00485758 |
|---|---|
| Title | Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | ER niacin/laropiprant, Comparator : placebo (unspecified) |
| Enrollment | 796 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jun 13, 2007 |
| Last update posted | Oct 12, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: